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Assembly of the eIF4E/eIF4G complex has
a central role in the regulation of gene expres-
sion at the level of translation initiation. This
complex is regulated by the 4E-BPs, which
compete with eIF4G for binding to eIF4E and
which have tumor-suppressor activity. To phar-
macologically mimic 4E-BP function we devel-
oped a high-throughput screening assay for
identifying small-molecule inhibitors of the
eIF4E/eIF4G interaction. The most potent com-
pound identified, 4EGI-1, binds eIF4E, disrupts
eIF4E/eIF4G association, and inhibits cap-
dependent translation but not initiation factor-
independent translation.While4EGI-1displaces
eIF4G from eIF4E, it effectively enhances 4E-
BP1 association both in vitro and in cells.
4EGI-1 inhibits cellular expression of oncogenic
proteins encoded by weak mRNAs, exhibits
activity against multiple cancer cell lines, and
appears to have a preferential effect on trans-
formed versus nontransformed cells. The identi-
ficationof this compoundprovidesanewtool for
studying translational control and establishes
a possible new strategy for cancer therapy.
INTRODUCTION
The regulation of gene expression at the level of transla-
tion initiation is critical for proper control of cellular growth,
proliferation, differentiation, and apoptosis. In eukaryotes
a set of initiation factors (eIFs) are required to dissociate
the 40S and 60S ribosomal subunits, to recruit themRNA and initiator tRNA to the 40S subunit, and to pro-
mote joining of the 60S subunit so that elongation can
commence (Dever, 2002; Hershey and Merrick, 2000).
The major rate-limiting step in initiation is thought to be lo-
calization of the small ribosomal subunit to the 50 end of
the mRNA. This process requires the stepwise assembly
of a large multiprotein complex centered on the trimer
eIF4F. eIF4F is composed of the cap-binding protein
eIF4E, the RNA helicase eIF4A, and the multidomain
adaptor protein eIF4G (Gingras et al., 1999; von der
Haar et al., 2004). Cap-bound eIF4F recruits the 40S ribo-
somal subunit through the eIF3/eIF4G interaction, which
initiates scanning to the initiation codon, where the 40S
subunit joins with the 60S subunit. This process is facili-
tated by eIF4A, with the requirement for its helicase activ-
ity directly proportional to the amount of secondary struc-
ture in the 50 untranslated region (UTR) that must be
melted for scanning to occur (Svitkin et al., 2001). All
eIF4G proteins bind eIF4E through a motif of sequence
Y(X)4LF, where X is variable and F is hydrophobic (Alt-
mann et al., 1997; Mader et al., 1995). This motif forms
a helical peptide structure that binds to a conserved sur-
face of hydrophobic residues on the dorsal side of eIF4E
(Marcotrigiano et al., 1999). In Saccharomyces cerivisiae
thismotif is part of a larger folded domain that forms an ex-
tended binding interface with eIF4E (Gross et al., 2003;
Hershey et al., 1999), but it is unclear whether a larger in-
terface exists in higher eukaryotes. Although the Y(X)4LF
motif may not be sufficient for full affinity binding of mam-
malian eIF4G to eIF4E, the fact that mutations in this se-
quence can abrogate binding indicates that it is necessary
for this protein-protein interaction (Mader et al., 1995).
Cellular mRNAs differ greatly in the amount of eIF4F
they require for efficient translation and in the composition
of their 50 UTRs. The majority of growth- and proliferation-
related proteins are encoded by ‘‘weak’’ mRNAs contain-
ing long, highly structured 50 UTRs that have lowerCell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc. 257
translational efficiency than ‘‘strong’’ mRNAs, which con-
tain relatively short and unstructured 50 UTRs (Lodish,
1976; Pickering and Willis, 2005). Translation of weak
mRNAs is highly eIF4F dependent and is preferentially
enhanced when the eIF4F complex level is increased by
eIF4E overexpression (Koromilas et al., 1992). The amount
of eIF4F in the cell is normally controlled by a class of small
proteins termed 4E-BPs (Pause et al., 1994) that seques-
ter eIF4E from eIF4G (Haghighat et al., 1995; Richter and
Sonenberg, 2005). These proteins contain the Y(X)4LF
sequence found in eIF4G, and, using this motif, they can
bindwith high affinity to the same surface of eIF4E (Marco-
trigiano et al., 1999). The activity of 4E-BPs is regulated by
hierarchical phosphorylation at a set of conserved serine
and threonine residues: hyperphosphorylated forms bind
much more weakly than hypophosphorylated forms, and
they are released from eIF4E (Gingras et al., 2001). The
kinase mTOR is the major upstream regulator of 4E-BPs:
stimuli such as nutrients and growth factors induce 4E-
BP phosphorylation and increased cellular eIF4F through
signaling pathways that activate mTOR (Averous and
Proud, 2006; Mamane et al., 2006; Petroulakis et al.,
2006; Tee and Blenis, 2005; Wullschleger et al., 2006).
Misregulation of cap-dependent translation plays an im-
portant role in human disease. A number of genetic disor-
ders characterized by aberrant cell growth, such as hyper-
trophic cardiopathy and tuberous sclerosis, are caused by
mutations that disregulate the mTOR pathway (Inoki et al.,
2005; Lee et al., 2006). Abnormal amounts of cellular eIF4F
caused by elevated levels of initiation factors or misregu-
lation of 4E-BP phosphorylation can play a key role in tu-
morigenesis (Bjornsti and Houghton, 2004; De Benedetti
and Graff, 2004; Petroulakis et al., 2006). Overexpression
of eIF4E (Avdulov et al., 2004; Lazaris-Karatzas et al.,
1990) or eIF4G (Fukuchi-Shimogori et al., 1997) can in-
duce malignant transformation in mammalian cells. Con-
versely, ectopic expression of 4E-BPs can partially revert
eIF4E-transformed cells to a nonmalignant phenotype
(Rousseau et al., 1996) and induce apoptosis in cells
transformed by other oncogenes such as Ras (Avdulov
et al., 2004; Li et al., 2002). Peptides containing the
Y(X)4LF motif also can induce apoptosis in mammalian
cells (Herbert et al., 2000). In transgenic mouse models,
eIF4E overexpression promotes tumorigenesis (Ruggero
et al., 2004; Wendel et al., 2004), while 4E-BP1 expression
suppresses it (Polunovsky et al., 2000). This is consistent
with the finding that, in humans, a variety of tumor types
exhibit elevated levels of eIF4E (Ruggero and Pandolfi,
2003). Thus, the eIF4F complex is considered to be an im-
portant target for cancer therapy. RNA that is antisense to
eIF4E has been shown to suppress the oncogenic proper-
ties of a head and neck carcinoma cell line (DeFatta et al.,
2000). In addition, several analogs of rapamycin, a drug
that decreases eIF4F levels by inhibiting mTOR-depen-
dent 4E-BP phosphorylation, have antitumor activity and
are being evaluated as cancer drugs in clinical trials
(Bjornsti and Houghton, 2004; Faivre et al., 2006; Huang
and Houghton, 2003; Sawyers, 2003).258 Cell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc.Chemical genetics is a powerful tool for the study of
cellular processes. High-throughput screens of com-
pound libraries have been successfully used to identify
new small-molecule modulators of translation initiation
(Bordeleau et al., 2005, 2006; Novac et al., 2004). An in-
creasingly important strategy in chemical genetics is the
identification of compounds that disrupt specific protein-
protein interactions (Arkin and Wells, 2004). Such inhibi-
tors potentially offer a highly selective way to modulate
the function of protein complexes and in many cases
have therapeutic potential. Extended protein-protein in-
terfaces typically contain ‘‘hot spots,’’ which are compact
regions of conserved residues that are critical for binding
affinity and that are attractive targets for the development
of small-molecule inhibitors. In the eIF4E/eIF4G interface
the group of conserved eIF4E surface residues that
contact the Y(X)4LF peptide constitute such a site. We
reasoned that small molecules that compete with this
peptide for binding to eIF4E would inhibit the eIF4E/
eIF4G interaction.
RESULTS AND DISCUSSION
Development of Fluorescence Polarization Assay
In order to identify compounds that disrupt the interaction
between eIF4E and the Y(X)4LF motif of eIF4G, we have
developed a high-throughput fluorescence polarization
(FP)-binding assay. A peptide containing the sequence
KYTYDELFQLK was synthesized and tagged with fluores-
cein. Titration of this peptide with eIF4E causes the FP and
the fluorescence anisotropy (FA) to increase almost 3-fold,
and fitting the data into previously described equations
(Roehrl et al., 2004) yields a peptide KD of 3 mM (Figure 1A).
As a positive control to validate the assay, the addition of
an unlabeled competitor eIF4GII peptide (with the se-
quence KKQYDREFLLDFQFMPA) was shown to cause
the FP to return to the level of free labeled peptide
(Figure 1B). Fitting of this data for the unlabeled peptide
yields an estimated KD of 200 nM. This is close to the pre-
viously reported value of 150 nM, which was determined
by isothermal titration calorimetry (Marcotrigiano et al.,
1999). Thus, the principle of the screen is to identify the
compounds that displace the labeled peptide from eIF4E
by detecting the resulting decrease in FP. For the initial
screen we used the 16,000 compound Chembridge Diver-
Set E library, fromwhich a compound that we have termed
4EGI-1 (for eIF4E/eIF4G interaction inhibitor) was identi-
fied (Figure 1D). Analysis of the labeled peptide displace-
ment caused by this compound as measured by FA
(which is directly related to FP) shows the compound is
a competitive inhibitor of eIF4G peptide binding (Fig-
ure 1C). In order to examine the specificity of 4EGI-1 we
have synthesized two analogs, 4EGI-1A and 4EGI-N
(Figure 1D). While 4EGI-N does not displace the labeled
peptide, 4EGI-1A has activity similar to that of 4EGI-1
(Figure 1C). Fitting these data to a three-component
(eIF4E, peptide, inhibitor) competition equilibrium yields,
for eIF4E binding of 4EGI-1 and 4EGI-1A, KD estimates
Figure 1. A FP Assay Identifies the Compound 4EGI-1 as a Competitive Inhibitor of the eIF4E/eIF4G Interaction
(A) Titration of a fluorescein-labeled eIF4G peptide with eIF4E causes increased FA. A best fit of the data to a two-state binding model is shown and
yields an estimated KD of 3 mM for binding of the labeled peptide to eIF4E.
(B) Competitive inhibition of labeled-peptide binding to eIF4E by an unlabeled eIF4GII peptide asmeasured by decrease in FA. A best fit of the data to
a three-state binding model is shown and yields a KD of 200 nM for the binding of the unlabeled peptide to eIF4E.
(C) Competitive inhibition of labeled-peptide binding toGB1-eIF4E by the compounds 4EGI-1 and 4EGI-1A. Full circles indicate 4EGI-N, empty circles
indicate 4EGI-1, and triangles indicate 4EGI-1A.
(D) Structures of the compounds 4EGI-1, 4EGI-N, and 4EGI-1A.of 25 mM ± 11 mM and 16 mM ± 6 mM, respectively. These
values provide rough estimates (as the errors indicate) of
the upper bound of the binding affinity for eIF4E. The
fact that 4EGI-1 and 4EGI-1A exist in two interconverting
isomeric forms in aqueous solution (see below) signifi-
cantly complicates fitting the multiple binding equilibria in-
volved and does not allow a more accurate determination
of the KDs.
Characterization of 4EGI-1 Interaction with eIF4E
by Nuclear Magnetic Resonance
Nuclear magnetic resonance (NMR) spectroscopy was
used to characterize the interaction of 4EGI-1 with
eIF4E. In order to confirm the direct binding of 4EGI-1 to
eIF4E, we titrated this molecule with perdeuterated pro-
tein and monitored the 1H-NMR spectrum of the com-
pound. Titration of 4EGI-1 causes significant line broaden-
ing of resonances in the spectrum of the compound,
which indicates binding to eIF4E (Figures 2A and S3). On
the other hand, a similar titration with the inactive analog
compound 4EGI-N shows little effect, which provides ev-
idence that the binding of 4EGI-1 is not due to nonspecific
hydrophobic interactions with the protein (Figure 2C). Ex-
amination of the 1H-NMR spectrum of 4EGI-1 in aqueoussolution shows that it can interconvert between the two
isomers and that one of the isomers is preferentially bound
by eIF4E. This does not allow a straightforward determina-
tion of a KD (see above). Replacement of one nitrogen with
a carbon (4EGI-N) eliminates this isomerization but also
renders the compound inactive.
We next wished to determine by chemical shift mapping
the location of 4EGI-1 interaction. Although chemical shift
assignments have been reported for a complex of murine
eIF4E with an eIF4G peptide (Miura et al., 2003), we
needed to determine assignments for the free protein.
Since mammalian eIF4E behaves poorly in solution, it
was necessary to develop a more soluble form of the pro-
tein. To accomplish this, an N-terminal fusion of eIF4E to
the 56 residue GB1 domain of protein G was constructed.
This fusion domain has been shown to act as a solubility
enhancement tag (SET) for heterologous proteins (Zhou
et al., 2001). The GB1-eIF4E fusion has greatly enhanced
solubility relative to that of native eIF4E. The presence of
the GB1 domain does not affect the structure of eIF4E
(Figure S1), and the fusion protein has the same binding
affinity for the eIF4G peptide in the FP assay. Using this
construct we obtained backbone chemical shift assign-
ments for mammalian eIF4E. We proceeded to titrateCell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc. 259
Figure 2. Characterization of the Interac-
tion of 4EGI-1 with eIF4E by NMR
(A) 1H-NMR spectra of 4EGI-1 measured at in-
creasing concentrations of perdeuterated
GB1-eIF4E indicate compound binding to
eIF4E as determined by the decrease in inten-
sity of peaks due to intermediate exchange
broadening. The presence of two sets of sig-
nals indicates introconversion of two isomers,
one of which binds preferentially to eIF4E, in
aqueous solution.
(B) Location of residues on the eIF4G-binding
surface of eIF4E with HSQC peaks that are
preferentially broadened when titrated with
4EGI-1. The surface representation of the
structure of eIF4E from the crystal structure of
the eIF4E/eIF4GII peptide complex (Marcotri-
giano et al., 1999) is shown with specific resi-
dues shaded in yellow. Image was generated
using MOLMOL (Koradi et al., 1996).
(C) 1H-NMR spectra of 4EGI-N measured at in-
creasing concentrations of perdeuterated
GB1-eIF4E indicate that the compound does
not bind eIF4E. The presence of only one set
of compound peaks indicates that this analog
does not isomerize (due to the replacement of
the central nitrogen with a carbon).
(D) Location of binding of the eIF4GII peptide.
The same surface representation as (C) is
shown from the same crystal structure with
the peptide drawn in blue.GB1-eIF4E with 4EGI-1 and to measure the effect on the
15N-HSQC spectrum (Figure S2). While no effect on the
GB1 resonances is observed, a set of the eIF4E peaks is
attentuated due to line broadening. This indicates specific
binding of the compound to eIF4E with intermediate ex-
change kinetics, which are typical of relatively tight li-
gand-protein interactions. Mapping the locations of the
surface-exposed residues that are the most attenuated
in intensity onto the structure of eIF4E (Figure 2B) shows
that they cluster around the site of eIF4G peptide binding
(Figure 2D). After extensive dialysis of fully titrated GB-
eIF4E to remove any bound compound this line broaden-
ing disappears, which indicates that the binding of 4EGI-1
to eIF4E is reversible (data not shown).
4EGI-1 Disrupts the eIF4F Complex and Inhibits
Cap-Dependent Translation In Vitro
We proceeded to characterize this compound in rabbit re-
ticulocyte lysate, which is a well-established in vitro model
system for studies of eukaryotic translation. To determine
if 4EGI-1 can disrupt the eIF4F complex, the compound
was incubated in rabbit reticulocyte lysate, and the state
of association of eIF4E with eIF4G and 4E-BP1 was deter-
mined by pull-down on m7GTP Sepharose resin (Fig-
ure 3A). This demonstrated that full-length eIF4G is dis-
placed from eIF4E by 4EGI-1 in a dose-dependent
manner. Surprisingly this compound does not inhibit bind-
ing of 4E-BP1 to eIF4E and instead causes a significant
apparent increase in the amount of this protein that is260 Cell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc.bound. The increase in the level of eIF4E-bound 4E-BP1
is approximately 2- to 4-fold, as estimated by western
blotting with purified 4E-BP1 as a concentration standard
(data not shown). We speculate that this effect is likely due
to the existence on eIF4E of a larger 4E-BP1 footprint that
partially overlaps with that of eIF4G. A number of previous
studies have provided strong evidence that this is the
case. NMR chemical shift mapping of yeast eIF4E titrated
with 4E-BP1 shows that there is a binding surface that is
larger than just the area of residues that interact with the
consensus peptide (Matsuo et al., 1997). Recently, it
was found that full-length 4E-BP1 binds to eIF4E with sig-
nificantly higher affinity than the consensus peptide alone
(Tomoo et al., 2006). To confirm that 4EGI-1 does not in-
hibit binding of 4E-BP1 to eIF4E, we carried out a pull-
down assay using purified eIF4E (without the GB1 tag)
and 4E-BP1. Concentrations of 4EGI-1 that would be ex-
pected to bind a significant proportion of the available
eIF4E do not cause any apparent decrease in 4E-BP1
binding (Figure 3B). Our data and the aforementioned
studies support a model in which 4EGI-1 displaces
eIF4G from eIF4E and clears the docking site for 4E-
BP1, thus effectively increasing the amount of the protein
bound to available eIF4E (Figure S4).
We then examined the effect of eIF4F complex disrup-
tion on translation in reticulocyte lysate using a dicistronic
mRNA construct that encodes two luciferases (Figure 3C).
The Renilla luciferase is translated in a cap-dependent
fashion, while translation of firefly luciferase is driven by
Figure 3. 4EGI-1 Disrupts eIF4F Complex Formation and Inhibits Cap-Dependent Translation
(A) 4EGI-1 displaces eIF4G from eIF4E and enhances 4E-BP1 binding in reticulocyte lysate. After incubation of aliquots of lysate with compound, cap-
affinity chromatography and SDS-PAGE immunoblotting were used to detect eIF4E, eIF4G, and 4E-BP1. The eIF4E lanes shown come from the same
gel and western blot.
(B) 4EGI-1 does not inhibit binding of purified 4E-BP1 to eIF4E. The two proteins were mixed in the presence of increasing compound concentrations
and subjected to cap-affinity chromatography. Silver staining was used to detect bound proteins. Purified eIF4E and 4E-BP1 are included on the gel
as molecular weight markers.
(C) Structure of a dual-luciferase mRNA reporter construct containing Renilla luciferase, the cricket paralysis virus IRES, and firefly luciferase.
(D) 4EGI-1 inhibits cap-dependentRenilla luciferase translation. Renilla luciferase activity was quantitated by measurement of luminescence and nor-
malized relative to a DMSO-treated control reaction. Data points represent mean of triplicate measurements with error bars corresponding to stan-
dard error of the mean.
(E) 4EGI-1 does not inhibit firefly luciferase translation. Firefly luciferase activity was quantitated by measurement of luminescence and normalized
relative to aDMSO-treated control reaction. Data points represent mean of triplicatemeasurements with error bars corresponding to standard error of
the mean.
(F) Effects of 4EGI-1 and its analogs on translation are correlated with inhibition of eIF4G peptide binding to eIF4E. Translation of Renilla and firefly
luciferases in reactions treated with 100 mM 4EGI-1, 4EGI-N, or 4EGI-1A was quantitated by luminescence measurements and was normalized to
a control reaction containing an equivalent percentage of DMSO. Data points represent mean of duplicate measurements with error bars correspond-
ing to standard error of the mean.the cricket paralysis virus IRES, which is independent of
initation factors (Pestova and Hellen, 2003). Cap-depen-
dent translation is inhibited by 4EGI-1 (Figure 3D), while
initiation factor-independent translation is not inhibited
and instead is enhanced (presumably due to increased
availability of ribosomes as cap-dependent translation is
shut down; Figure 3E). The inactive analog 4EGI-N hasno significant effect on cap-dependent or IRES-driven
translation, while the active analog 4EGI-1A has an effect
similar to that of 4EGI-1 (Figure 3F).
Next we examined the effect of 4EGI-1 on translation of
the HCV and EMCV IRESs, both of which utilize transla-
tion-initiation factors. In rabbit reticulocyte lysate, 4EGI-
1 can inhibit translation from the EMCV IRES at higherCell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc. 261
Figure 4. 4EGI-1 Disrupts the eIF4F
Complex and Inhibits Expression of
Oncogenic Proteins in Mammalian Cells
(A) 4EGI-1 displaces eIF4G from eIF4E and en-
hances 4E-BP1 binding in Jurkat cells. After
6 hr treatment with compound, extract prepa-
ration, cap-affinity chromatography, and
SDS-PAGE immunoblotting were used to de-
tect eIF4E, eIF4G, and 4E-BP1.
(B) Effect of 4EGI-1 on total eIF4G, 4E-BP1,
and 4E-BP1 phosphorylation. After 6 hr treat-
ment with compound, preparation of total cell
extracts and SDS-PAGE immunoblotting were
used to detect eIF4G, 4E-BP1, 4E-BP1 phos-
phorylated at T37/46, and 4E-BP1 phosphory-
lated at T70. An immunoblot for b-actin is
shown as a control for total protein in the
extract.
(C) 4EGI-1 downregulates expression of the
c-Myc and Bcl-xL proteins. After 8 hr treatment
with compound, preparation of total cell ex-
tracts and SDS-PAGE immunoblotting were
used to detect b-actin, c-Myc, and Bcl-xL.
(D) 4EGI-1 does not affect the cytosolic levels
of c-myc and Bcl-xL mRNAs. After 8 hr treat-
ment with compound, preparation of cytosolic mRNA, and cDNA synthesis, the amount of mRNA relative to b-actin mRNA was quantitated by
real-time PCR using the DDCt method. Data points represent mean of triplicate measurements with error bars corresponding to standard error of
the mean.concentrations than needed to inhibit cap-dependent
translation (Figure S5). One explanation for this could be
that the efficiency of translation from the EMCV IRES is af-
fected by the binding of eIF4E to eIF4G. Although this
IRES does not directly require eIF4E, it does require
eIF4G, and conformational changes in eIF4G caused by
eIF4E binding may affect the efficiency of initiation from
this IRES, at least in vitro. It is also possible that the com-
pound has some ‘‘off-target’’ effects at the concentrations
used in this study and inhibits the function of an additional
factor or factors involved in EMCV IRES-driven transla-
tion. The HCV IRES is also inhibited by 4EGI-1 at a higher
concentration than that needed to inhibit cap-dependent
translation (Figure S5), which also could be due to ‘‘off–
target’’ effects.
Activity of 4EGI-1 in Mammalian Cells
In order to determine if 4EGI-1 can disrupt the eIF4F com-
plex in cells as well as in extracts we examined the effect
of this compound on Jurkat leukemia T cells. Similar to the
effect in vitro, compound treatment causes eIF4G to be
displaced from eIF4E, while binding of 4E-BP1 is in-
creased (Figure 4A). The total cellular levels of eIF4G
and 4E-BP1 do not change significantly under these con-
ditions, and there does not appear to be proteolytic cleav-
age of these proteins (Figure 4B). A possible alternative
explanation for this result is that 4EGI-1 disrupts the path-
ways controlling phosphorylation of 4E-BP1. To test this
possibility, we examined the cellular levels of phosphory-
lated forms of 4E-BP1 relative to total 4E-BP1 and found
that they are not affected by the compound treatment
(Figure 4B). This leads us to conclude that the displace-262 Cell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc.ment of eIF4G is due to binding of 4EGI-1 to eIF4E. Both
in vitro and in cells, the estimated IC50 for displacement
of eIF4G from eIF4E is similar to that for inhibition of
cap-dependent translation (Table S1). The in vitro IC50
values for displacement of full-length eIF4G and for inhibi-
tion of cap-dependent translation are lower than that in the
FP assay. This is presumably due to the lower level of
eIF4E. We proceeded to examine the effect of 4EGI-1 on
protein expression, hypothesizing that this compound
would downregulate proteins encoded by weak mRNAs
while having little effect on those encoded by strong
mRNAs. In extracts of Jurkat cells treated with 4EGI-1, ex-
amination of protein levels by western blotting showed
that the level of b-actin (which has a short, unstructured
50 UTR) is unaffected, while expression of c-myc and
Bcl-xL (both of which have long, highly structured 50
UTRs) is signficantly decreased (Figure 4C). b-actin is
a classic housekeeping protein and is encoded by a strong
mRNA, while c-Myc and Bcl-xL are both oncogenic pro-
teins encoded by weak mRNAs. To rule out the possibility
of downregulated transcription or nucleocytosolic trans-
port, cytosolic mRNA was prepared from treated cells,
and quantitative real-time PCR was used to determine
the effect of compound treatment on the levels of c-myc
and Bcl-xL mRNAs. No significant change in mRNA level
with increasing compound concentration was observed
(Figure 4D).
Since regulation of cap-dependent translation plays an
important role in cell survival, we wished to examine
whether 4EGI-1 can induce apoptosis. Incubation of Ju-
rkat cells with the compound induces cell death after 24
hr, as determined by measurement of the intracellular
Figure 5. 4EGI-1 Has Proapoptotic Activity and Inhibits the Growth of Multiple Cancer Cell Lines
(A) 4EGI-1 treatment causes cell death in the Jurkat cell line. Twenty-four hours after addition of the compound, cell viability was quantitated by ad-
dition of CellTiter Glo reagent and by measurement of luminescence. Viability was normalized relative to DMSO-treated control cells. Data points
represent mean of triplicate measurements with error bars corresponding to standard error of the mean.
(B) 4EGI-1 causes a significant increase in the cellular subG1 DNA content that is suppressed by cotreatment with zVAD-FMK. After 24 hr treatment
with varying combinations of compounds, the percentage of total cells having a subG1 DNA content was determined by propidium iodide staining
and by sorting in a FACS machine. Bars represent the mean of triplicate measurements with error bars corresponding to standard error of the mean.
(C) 4EGI-1 causes an apoptotic nuclear morphology. After 24 hr treatment with DMSO (control) or 60 mM 4EGI-1, cells were stained with Hoechst
33342 and visualized by fluorescence microscopy. Representative micrographs of control and treated cells are shown.
(D) 4EGI-1 treatment inhibits the proliferation of A549 lung cancer cells. Five days after cells were seeded at low density and compound was added,
the level of cell proliferation was quantitated by SRB staining and by absorbance measurement. Proliferation was normalized relative to DMSO-
treated control cells. Data points represent mean of triplicate measurements with error bars corresponding to standard error of the mean.
(E) 4EGI-1 treatment preferentially inhibits the growth of transformed pH+ cells but not nontransformed pH cells. Three days after cells were seeded
at low density and treatedwith compound, the level of cell growthwas quantitated using a BeckmanCoulter cell counter. Proliferation was normalized
relative to DMSO-treated control cells. Data points represent mean of three independent experiments with error bars corresponding to standard error
of the mean.ATP level using a luminescent assay (Figure 5A). To find
out if this cytotoxic activity is due to induction of apopto-
sis, we determined the ability of 4EGI-1 treatment to cause
DNA fragmentation. Compound treatment causes a signif-
icant increase in subG1 DNA content in treated cells
(Figure 5B); this is suppressed by cotreatment with the
caspase inhibitor zVAD-FMK. In addition, the nuclei of
treated cells have a fragmented morphology that is char-
acteristic of apoptosis (Figure 5C). The demonstration
that 4EGI-1 has proapoptotic activity in Jurkat cells sug-
gested that this compound may exhibit activity against
other cancer cell lines. The effect of this compound was
tested using the NCI-SRB assay on A549 lung cancer cells
(Figure 5D). This demonstrated that 4EGI-1 potently in-
hibits cell growth with an IC50 of approximately 6 mM. Be-cause translation of weak mRNAs is highly sensitive to the
level of eIF4F in the cell, it is likely that even small de-
creases in the level of this complex can cause a dispropor-
tionate biological effect in cells. This would explain why
the observed IC50 values for apoptosis of Jurkat cells
and the inhibition of A549 cell proliferation are lower
than both the estimated affinity of 4EGI-1 for eIF4E and
the IC50 for displacement of eIF4G from eIF4E (Table
S1). One prediction that we made was that 4EGI-1 will
have a stronger effect on transformed cells than on non-
transformed cells due to the greater sensitivity of the for-
mer to inhibition of cap-dependent translation. To deter-
mine if this compound has a preferential effect on
isogenic-transformed versus -nontransformed cells, we
tested its effect on the growth of the Ph+ cell line, whichCell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc. 263
is transformed by the bcr-abl oncogene. For comparison
purposes we used Ph cells, which are from an isogenic
cell line that is not transformed. Testing the effect of the
compound on cell growth showed that 4EGI-1, with an
IC50 for Ph
+ cells more than 2-fold lower than for Ph cells
(Figure 5E), has a significantly more potent effect on trans-
formed cells.
Conclusions
Our results demonstrate that it is possible to inhibit the
protein-protein interaction between eIF4E and eIF4G
using small molecules, and establish a methodology that
can readily be used to identify new classes of such inhib-
itors through the screening of compound libraries. Major
goals for future studies include a more detailed character-
ization of the mechanism of 4EGI class compounds in
mammalian cells and a determination of how specific
these compounds are for inhibition of eIF4E/eIF4G com-
plex formation and for cap-dependent translation. This
will be facilitated by synthesis of a larger set of analogs
of 4EGI-1 for use in structure-activity studies. In addition,
experimental modulation of eIF4E, eIF4G, and/or 4E-BP
levels in cells treated with these compounds will aid in
evaluating their specificity.
The observation that 4EGI-1 inhibits the binding of
eIF4G, but not 4E-BP1, to eIF4E is somewhat unexpected
and of particular interest. By shifting the equilbrium away
from eIF4E/eIF4G complexes in favor of eIF4E/4E-BP1
complexes, 4EGI-1 appears to effectively enhance the ac-
tivity of 4E-BP1. Although both eIF4G and 4E-BP1 contain
the same Y(X)4LF-consensus motif, there is evidence that
the binding footprint of 4E-BP1 may be larger and may in-
volve contacts outside of this sequence. Up to this point
attempts to determine the structure of the complex of
eIF4E by using full-length 4E-BP1 (as opposed to smaller
peptides) have not been successful due to the presence of
extensive NMR line broadening in the complex and the
failure of this complex to crystallize. It is possible that dis-
placement of eIF4G from eIF4E by 4EGI-1 may free up the
binding site for 4E-BP1 by removing steric obstruction.
Future structural studies will reveal the molecular basis
of the specificity of inhibition of eIF4G binding to eIF4E
by 4EGI compounds.
Small-molecule inhibitors of the eIF4E/eIF4G interac-
tion provide a novel chemical genetic tool with which to in-
vestigate translational control of gene expression. This
approach could potentially be used in the study of the
many cellular processes, such as cell growth, embryonic
development, apoptosis, synaptic plasticity, and axon
guidance, in which translational control is involved. Our re-
sults also show that antagonists of the eIF4E/eIF4G inter-
action make up a potential new strategy for small-mole-
cule cancer therapy. Disregulation of a large number of
signaling pathways can cause cellular transformation,
and many of these pathways converge upon the regula-
tion of cap-dependent translation initiation. It is likely
that inhibition of cap-dependent translation will thus
have therapeutic value against a wide range of cancer264 Cell 128, 257–267, January 26, 2007 ª2007 Elsevier Inc.types. Although the compound 4EGI-1 is clearly not in
the potency range of a lead drug candidate, it does pro-
vide a pharmacophore that can be used to develop inhib-
itors with higher binding affinity for eIF4E through synthe-
sis of libraries of analogs of this compound and through
rational design. The determination of the structure of
4EGI-1 or of a tighter binding analog in complex with
eIF4E will facilitate this process. In addition, the assay de-
veloped in this study can readily be used to screen more
and larger libraries of synthetic compounds and natural
products to identify other lead compounds. Such mole-
cules could have higher affinity themselves or, if they are
found to bind at a different site than 4EGI compounds,
could be linked to this scaffold to generate a tighter bind-
ing inhibitor structure.
EXPERIMENTAL PROCEDURES
Protein Cloning, Expression, and Purification
The fusion protein GB1-eIF4E was constructed by cloning the full cod-
ing sequence of murine eIF4E into a GB1 expression vector between
the BamHI and EcoRI restriction sites. The sequence of murine
eIF4E is identical to human eIF4E in the structured portion of the pro-
tein with the exception of the substitution of an E for D174, which is
a nonconserved residue. Both the tagged and native forms of murine
eIF4E were expressed in Escherichia coli in LB or isotopically labeled
M9 media, then purified by cap-affinity chromatography on m7GDP
or m7GTP agarose resin. The affinity resin was prepared as previously
described (Edery et al., 1988).
FP/FA Assays
The C-terminal fluorescein-labeled peptide has sequence KYTY
DELFQLK and was synthesized by Research Genetics. This sequence
contains the Y(X)4LFmotif andwas optimized for solubility and binding
to eIF4E. The unlabeled eIF4GII peptide has the sequence KKQY
DREFLLDFQFMPA and was synthesized at the Tufts University Core
facility. For the screening assay a solution containing approximately
5 mM eIF4E, 60 nM labeled peptide, 0.05% bovine g-globulin, and 2
mM DTT in a buffer composed of 50 mM sodium phosphate and 50
mM potassium chloride at pH 6.5 was used. Measurements of FP
and FA were made in black 384-well plates (Corning) using an Analyst
plate reader (LJL Biosystems). Compounds were transferred to plates
using a custom-built Seiko pin-transfer robot at the Institute for Chem-
istry and Cell Biology at Harvard Medical School. Both GB1-eIF4E and
native eIF4E behave identically in this assay. For measurements of FA
to be used in curve fitting, the labeled peptide concentration was
increased to 1 mM, and g-globulin was omitted. The curve fitting for
estimation of binding constants used a set of equations based on
two- and three-state binding models that were derived by Michael
Roehrl as previously described (Roehrl et al., 2004).
NMR Spectroscopy
Protein samples for NMR were prepared in a buffer composed of 50
mM sodium phosphate, 50 mM potassium chloride, and 2 mM DTT
at pH 6.5. For protein samples of very high concentration (>300 mM)
the DTT concentration was 20 mM. In the backbone assignment ex-
periments, the protein was isotopically labeled with 15N, 13C, and
85% or 90% deuterium. The standard three pairs of triple resonance
experiments were recorded: HNCA/HN(CO)CA, HNCO/HN(CA)CO,
and HNCACB/HN(CO)CACB. The HNCA/HN(CO)CA dataset was re-
collected using a higher protein concentration and TROSY versions
of the pulse sequences in order to obtain data with higher sensitivity.
In addition, a 15N-HSQC-NOESY experiment, HSQCs of spe-
cific 15N-Lys-, 15N-Ile-, 15N-Leu-, and 15N-Val-labeled samples of
GB1-eIF4E and an HSQC of a reverse-Arg-labeled sample were re-
corded to facilitate the backbone assignments. For 1H titration exper-
iments of compounds with GB1-eIF4E the compound concentration
was 40 mM, and perdeuterated protein was used. For the 15N-HSQC
titration the GB1-eIF4E concentration was 25 mM, and the protein
was fully protonated. NMR data were processed using NMRPipe (De-
laglio et al., 1995), and NMR spectra were analyzed using the software
packages XEASY (Bartels et al., 1995) and CARA (which can be
downloaded from www.nmr.ch; Keller, 2004).
In Vitro Translation Assays
The dicistronic reporter construct that contains the Renilla reniformis
luciferase sequence after the 50 UTR, followed by the CrPV IRES and
the firefly luciferase sequence, has been previously described (Wilson
et al., 2000) and was generously provided by Tatyana Pestova. The re-
porter construct plasmid was linearized with BamHI and transcribed
in vitro with an ARCA cap using the mMessage Machine T7 Ultra Kit
(Ambion). In vitro translation reactions were carried out using Red
Nova reticulocyte lysate (Novagen) with 2 mM magnesium acetate
and 153 mM potassium acetate, which was incubated at 30C for
90 min. Translation of reporter genes was measured using the Dual-
Glo luciferase assay (Promega) in a Wallac Victor2 plate reader. For
measurement of translation from the HCV IRES and EMCV IRES, the
previously described dicistronic reporter constructs were used (Bor-
deleau et al., 2006). Uncapped mRNA containing the HCV IRES or
EMCV IRES was prepared using the Megascript T3 kit (Ambion), and
in vitro translation reactions were run in rabbit reticulocyte lysate as
for the CrPV IRES construct.
m7GTP Pull-Down Assay
For the in vitro version of the assay, aliquots of Red Nova reticulocyte
lysate with the same salt and buffer concentrations as in the translation
reactions were incubated with compound or 200 mMm7GDP for 1 hr at
37C. Following incubation the lysate was incubated with m7GTP-
Sepharose beads (Pharmacia) for 1 hr at 4C. After washing of the resin,
the bound proteins were eluted with free m7GTP, resolved by SDS-
PAGE, and analyzed by western blotting using a polyclonal antibody
against 4E-BP1 (Cell Signaling Technology) and monoclonal anti-
bodies against eIF4E and eIF4G (Transduction Laboratories). For anal-
ysis of binding of purified eIF4E to purified 4E-BP1, the two proteins
were mixed (with eIF4E at 920 nM concentration and 4E-BP1 at 770
nM concentration) and subjected to the same protocol as above,
with bound eIF4E and 4E-BP1 detected by silver staining using the Sil-
verQuest kit (Invitrogen). Purified 4E-BP1 was obtained from Santa
Cruz Biotechnology. For the cell-based version of the assay, Jurkat
cells were grown for 6 hr in the presence of the compound, harvested
by centrifugation, and lysed by multiple freeze-thaw cycles. Extracts
prepared by this method were analyzed using the same pull-down pro-
tocol as with the reticulocyte lysates. Phosphorylated forms of 4E-BP1
were detected using polyclonal antibodies (Cell Signaling Technology).
Cell Culture Experiments
For analysis of cellular protein and mRNA levels, Jurkat cells were
grown for 8 hr in the presence of the compound. Extracts for protein
analysis were prepared from half of the cells by multiple freeze-thaw
cycles. The levels of b-actin, Bcl-xL, and c-Myc were analyzed by
western blotting using protein-specific polyclonal antibodies (Cell Sig-
naling Technology). The other half of the cells was used formRNA anal-
ysis. The PARIS kit (Ambion) was used to isolate separate fractions of
cytosolic and nuclear RNA. As described in the PARIS manual, aga-
rose gel electrophoresis was used to confirm the integrity of the frac-
tionation. Trace DNA was removed from the cytosolic fraction using
the DNA-free kit (Ambion), and cDNA was prepared using MMLV re-
verse transcriptase (Promega). Real-time PCR quantitation of c-myc
andBcl-xLmRNA relative to b-actin was done using theDDCTmethod.
Real-time PCRwas performed in triplicate with an Applied Biosystems
thermocycler using the QuantiTec SYBR Green Kit (Qiagen).Sequence-validated QuantiTec probes (Qiagen) were used for the
c-myc, the Bcl-xL, and the b-actin mRNAs.
Cell viability was measured by treatment of Jurkat cells with com-
pound for 24 hr and by determination of intracellular ATP using the
CellTiterGlo assay (Promega). For measurement of apoptotic DNA
fragmentation, cells were treated for 24 hr with 60 mM EGI-1 or 6.65
mM camptothecin in the presence or absence of 100 mM zVAD-FMK,
a broad-spectrum caspase inhibitor. After fixation and staining with
PI, cellular DNA content was determined by FACS analysis in a FACS-
Calibur machine (Beckton Dickinson). Nuclear morphology after 24 hr
EG1-1 treatment was visualized by staining of cells with Hoechst
33342 dye and fluorescence microscopy. For the A549 lung cancer
cells, cell growth in the presence of 4EGI-1 was determined using
the SRB staining method as previously described (Fan et al., 2004).
To determine the selectivity of eIF4E/4G inhibitors for transformed
cells, we employed two isogenic cell lines: nontransformed mouse
Ba/F3 cells and Ba/F3 cells transformed through transfection with
p210 bcr/abl, which were termed Ph and Ph+ cells, respectively (Da-
ley and Baltimore, 1988; both lines were kind gifts from Dr. James Grif-
fin at the Dana Farber Cancer Institute). Cells were cultured in the pres-
ence of 5% CO2 at 37
C in RPMI 1640 medium supplemented with
10% fetal calf serum, WEHI 3B-conditioned medium as a source of
IL-3, and penicillin/streptomycin. Cells were plated to 12-well plates
at a density of105 cells/ml in 2mlmedia andwere treated in duplicate
with increasing concentration of eIF4E/4G inhibitor keeping DMSO
concentration constant. On day 3 a 100 ml aliquot was removed from
every well, and cell numbers were determined in a Beckman Coulter
cell counter.
Supplemental Data
Supplemental Data include one table and five figures and can be found
with this article online at http://www.cell.com/cgi/content/full/128/2/
257/DC1/.
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